Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies

Summary

Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a high eradication rate for clarithromycin-resistant strains, and have a great potential to replace bismuth quadruple therapy in the treatment of H. pylori infection.

Timeline

Start

2018-09-03

Primary completion

2021-12-31

Completion

2021-12-31

Publications

• Hsu PI, Chen KY, Tai WC, Yang JC, Tsay FW, Liu YH, Chen CL, Lee CL, Yeh HZ, Kuo CH, Chuah SK, Lee HC, Shie CB, Shiu SI, Kao JY, Yamaoka Y, Graham DY, Wu DC; Taiwan Acid-related Disease (TARD) Study Group. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 Jul 1;118(7):1184-1195. doi: 10.14309/ajg.0000000000002255. Epub 2023 Mar 20.

Drugs

Indications